GlassScriptPhysician profile
Sean D Hyman
NPI 1780682120
$2,857.22
in general payments reported to CMS, 2019-2025
18 companies · $660 in 2025
The $660 reported for 2025 was more than what 84% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $360 · 2020: $30.46 · 2021: $188 · 2022: $279 · 2023: $506 · 2024: $834 · 2025: $660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,000.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $417.97 | 2021-2025 | Myday Contact Lens, Misight Contact Lens, Clariti Contact Lens |
| Allergan, INC. | $289.80 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $268.46 | 2024-2025 | Miebo, Xiidra |
| Sun Pharmaceutical Industries INC. | $267.23 | 2023-2025 | Cequa |
| Abbvie INC. | $255.14 | 2023-2025 | |
| Lkc Technologies, INC. | $222.37 | 2024-2025 | |
| Alcon Vision LLC | $167.44 | 2024 | Total30, Dailies Total1, Precision 1 |
| Astellas Pharma Global Development | $150.00 | 2024 | Izervay |
| Biotissue Holdings INC. | $140.00 | 2025 | |
| Glaukos Corporation | $128.26 | 2022 | |
| Dompe US, INC. | $124.00 | 2023 | Oxervate |
| Shire North American Group INC | $124.00 | 2019 | |
| Apellis Pharmaceuticals, INC. | $109.99 | 2024 | Syfovre |
| Maculogix, INC. | $78.44 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $52.61 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $31.05 | 2019-2024 | |
| Carl Zeiss Meditec Ag | $17.20 | 2020 | |
| Novartis Pharmaceuticals Corporation | $13.26 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Hyman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.